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Abstract 
Persistent dysregulation of the DNA damage response and repair in cells causes genomic instability. The resulting 
genetic changes permit alterations in growth and proliferation observed in virtually all cancers. However, an unstable 
genome can serve as a double-edged sword by providing survival advantages in the ability to evade checkpoint sign-
aling, but also creating vulnerabilities through dependency on alternative genomic maintenance factors. The Fanconi 
anemia pathway comprises an intricate network of DNA damage signaling and repair that are critical for protection 
against genomic instability. The importance of this pathway is underlined by the severity of the cancer predisposing 
syndrome Fanconi anemia which can be caused by biallelic mutations in any one of the 21 genes known thus far. This 
review delineates the roles of the Fanconi anemia pathway and the molecular actions of Fanconi anemia proteins in 
confronting replicative, oxidative, and mitotic stress.
Keywords: DNA damage response, DNA repair, Fanconi anemia, FANCA, Genome instability
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Genomic instability and Fanconi anemia
The study of genomic instability as a potent driver of 
malignancy has placed an ever-growing importance on 
understanding the molecular players that contribute 
to the protection of the genetic code within each cell. 
Genome instability is defined as an acquired state that 
allows for an increased rate of spontaneous genetic muta-
tions throughout each replicative cell cycle [1]. Three 
different types of genomic instability are recognized: (1) 
microsatellite instability (MI) which is characterized by 
random insertions or deletions of several base pairs in 
microsatellite sequences. MI is commonly observed in 
hereditary colorectal carcinomas, with defects in mis-
match repair proteins. (2) Nucleotide instability causes 
subtle sequence changes as a result of DNA polymer-
ase infidelity, aberrant base excision repair (BER) or 
nucleotide excision repair (NER). (3) Chromosomal 
instability (CIN) is the most frequently observed type 
of genome instability and has the greatest potential to 
lead to oncogenic transformation. CIN is responsible 
for translocations, inversions, deletions, aneuploidy, and 
other chromosomal changes that can vary from cell to 
cell [1]. The significance of these genomic instabilities 
in promoting pro-oncogenic events is highlighted by 
the presence of at least one type in almost all cancers at 
every stage of progression, and in hereditary and spo-
radic cancers alike [2]. The ubiquity of genomic instabil-
ity in tumor cells has called for its inclusion as a hallmark 
of cancer, although the mechanism by which it arises has 
shown to differ between cancers of genetic or spontane-
ous origin. Germline mutations of DNA damage repair 
genes predispose individuals to cancer development 
through acquisition of a “mutator phenotype”. A muta-
tor phenotype allows for higher rates of genetic mutation 
to occur due to reduced or absent expression of ‘care-
taker genes’ that function in ensuring that aberrant DNA 
sequence changes are corrected before being passed on 
to newly divided daughter cells. An accumulated amount 
of unrepaired damage and errors could then result in 
the ability to avoid checkpoint mechanisms and further 
mutate genes that are essential for regulating cellular 
growth signaling and proliferation. The origin of spo-
radic cancers is much more elusive, but is hypothesized 
to arise from replication stress and its related mecha-
nisms [3]. Because little is known about the mechanisms 
Open Access
Cell & Bioscience
*Correspondence:  yzhang4@med.miami.edu 
Department of Biochemistry and Molecular Biology, University of Miami 
Miller School of Medicine, Gautier Building Room 311, 1011 NW 15th 
Street, Miami, FL 33136, USA
Page 2 of 18Palovcak et al. Cell Biosci  (2017) 7:8 
of sporadic oncogenesis, hereditary cancer-predisposing 
diseases serve as excellent models for studying the pro-
teins and pathways that are altered to be tumorigenic.
Fanconi anemia (FA) is one such disease model that 
holds the potential to uncover the activities of a group 
of proteins that have prominent roles in genome main-
tenance. FA is a rare, inherited chromosomal instabil-
ity disorder caused by biallelic mutation in one of the 
21 known complementation groups [4–9]. Because FA 
proteins mediate DNA interstrand crosslink repair, cells 
from affected patients show hypersensitivity to crosslink-
ing agents such as Mitomycin C (MMC), Diepoxybutane 
(DEB) and Cyclophosphamide. The increased amount 
of chromosome breaks observed in FA cells upon treat-
ment with DEB is used as a diagnostic tool to confirm 
that an individual does indeed harbor a mutation within 
one of the Fanconi anemia genes [10]. Consistent with 
the association of genome integrity with carcinogenesis, 
FA patients suffer from myeloid leukemias, liver tumors, 
head and neck carcinomas, and gynecologic malignancies 
more frequently and at a younger age than the general 
population [11, 12]. Blood related pathologies contrib-
ute to the most severe symptoms of FA as the probability 
of developing myelodysplasia and acute myeloid leuke-
mia (AML) in FA patients is 30–40% by 40 years of age. 
Sequencing studies and FISH analysis have shown that 
amplifications of certain oncogenes due to chromosomal 
translocations are responsible for blood cancers in FA 
patients [13]. It was found that hematopoietic regulating 
transcription factor RUNX1 is often altered as a result of 
balanced and unbalanced translocations in both FA and 
non-FA cases of AML, indicating that the etiologies of 
FA-associated genome instability are relevant for study-
ing carcinogenesis in populations unaffected by FA [13]. 
The functions of the Fanconi anemia proteins can be clas-
sified into several separate groups based on each one’s 
role in their canonical pathway of interstrand crosslink 
repair. Group 1 is classified as the core complex, which 
consists of FANCA, FANCB, FANCC, FANCE, FANCF, 
FANCG, FANCL, FANCM, along with Fanconi Anemia 
Associated Proteins FAAP100, FAAP20, FAAP24 [5, 
14]. Although the entire function of the core complex 
is not completely understood, multimerization of the 
Group 1 proteins is necessary for monoubiquitination 
of FANCD2–FANCI upon recognition of cross-linked 
DNA in the presence of an ubiquitin conjugating enzyme 
UBE2T/FANCT [15–20]. The group 2 FANCD2–FANCI 
or the ID complex, once activated by monoubiquitina-
tion, recruits group 3 DNA repair factors that are criti-
cal for resolving interstrand crosslinks sensed during S 
phase [21]. Group 3 proteins are the downstream repair 
factors DNA endonuclease XPF/FANCQ, nuclease scaf-
folding protein SLX4/FANCP, translesion synthesis 
factor REV7/FANCV, and Homologous Recombina-
tion Proteins BRCA2/FANCD1, BRIP1/FANCJ, PALB2/
FANCN, RAD51C/FANCO, RAD51/FANCR, BRCA1/
FANCS, and XRCC2/FANCU [7, 22–24] (Biallelic muta-
tions of XRCC2 are only found from cells derived from a 
previously identified patient, thus more XRCC2 patients 
are needed to confirm XRCC2 as a FA gene). The repair 
capacities of FA proteins in the occurrence of interstrand 
crosslinks, in themselves, contribute to the proteins roles 
as ‘caretakers’ and keepers of genome stability. However, 
recently elucidated functions of these proteins in other 
pathways broaden the spectrum of ways that they con-
tribute to genome stability as well as ways that they may 
contribute to the mechanisms of sporadic cancers.
FA proteins function in overcoming replication 
stress
Replication stress occurs when a structure or lesion pre-
sent within DNA obstructs replication machinery and 
causes stalling [25]. The source of replication stress must 
be repaired without alterations to the genomic sequence 
in a timely manner in order to avoid deleterious fork col-
lapse. Fork collapse increases the chances of producing a 
genetically unstable cell by allowing for incomplete repli-
cation and subsequent deletions and translocations that 
perpetuate these replication errors throughout remaining 
cell divisions.
Interstrand crosslink repair
One of the primary protective roles of FA proteins is their 
assistance of replication fork recovery at stalled inter-
strand crosslinks (ICLs). ICLs completely block replica-
tion fork progression by covalently linking both strands 
of the DNA double helix, creating a lesion so cytotoxic 
that a single cell can withstand only 20–60 at one time 
[26]. Exogenous sources of ICLs include chemothera-
peutic agents Mitomycin C, Diepoxybutane, and Nitro-
gen Mustards. ICLs can also form endogenously through 
linkage of the C4′-oxidized abasic site (C4-AP) with an 
adenine (dA) site present at the position opposite the 3′ 
neighboring nucleotide [27, 28]. It has also been demon-
strated in vitro that aldehydes are able to react with the 
exocyclic amino group of a DNA base, forming an alde-
hyde/DNA adduct that can further be processed into an 
ICL [29, 30]. There are abundant sources of endogenous 
aldehydes such as acetaldehyde produced from ethanol 
metabolism or malondialdehyde, and crotonaldehyde 
from lipid peroxidation [30]. In vivo studies have shown 
bone marrow cells of FANCD2 null mice to be hyper-
sensitive to aldehyde accumulation, which supports the 
necessity of ICL repair by the FA pathway for manage-
ment of the damage caused by these reactive endogenous 
species [31]. The first event of ICL repair occurs during S 
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phase and requires convergence of two replication forks 
on an interstrand crosslink [32]. When the replication 
machinery stalls at an ICL, the CMG helicase complex is 
unloaded from chromatin in a BRCA1 (FANCS)-BARD1 
dependent manner [33] (Fig.  1). It is proposed that 
FANCM is responsible for recognizing the ICL lesion, 
and then inducing the recruitment of the downstream 
factors within the FA pathway that are necessary to carry 
out repair [34], the events of which take place through the 
following mechanism: FANCA, FANCG, and FAAP20 
associate to form one subcomplex within the FA core, 
while FANCE, FANCF, and FANCC form another sub-
complex [35] (Fig. 1a). The exact purpose of this subcom-
plex formation is unknown, however the multimerization 
of 8 FA proteins (FANCA, FANCB, FANCC, FANCE, 
FANCF, FANCG, FANCL, FANCM) along with 5 FA-
associated proteins (FAAP100, FAAP24, HES1, MHF1, 
and MHF2) results in a 13-subunit ubiquitin ligase that 
functions to monoubiquitinate the FANCD2–FANCI 
heterodimer [34, 36] (Fig.  1b). Although recent in  vitro 
studies have suggested that removal of one of the sub-
complexes (A-G-20 or F-E-C) weakens the ubiquitination 
of the FANCD2–FANCI complex, removal of both sub-
complexes is necessary to completely ablate the ubiquitin 
ligase activity of the core complex [35]. Because FANCA 
has DNA binding activity and regulates MUS81–EME1 
endonuclease activity in an ICL damage-dependent man-
ner [37, 38], it could contribute to chromatin localization, 
Fig. 1 Interstrand crosslink sensing by the Fanconi anemia pathway. a The CMG helicase encounters ICL damage at the replication fork. b FANCM 
could be the primary factor in recognizing the interstrand crosslink upon replication folk stall. After damage verification presumably by FANCA, 
assembly of the FA core complex on the ICL site provokes the ubiquitin ligase activity of FANCL and results in monoubiquitination of FANCD2–
FANCI complex, which further recruits downstream nucleases, polymerases, and DSB repair factors for the procession and repair of ICL
Page 4 of 18Palovcak et al. Cell Biosci  (2017) 7:8 
ICL damage verification, and the attachment of the 
subcomplex to DNA at the site of lesion. The ubiquitin 
ligase function of FANCL is dependent on its catalytic 
subcomplex consisting of FANCB and FAAP100 (B-L-
100), which are also present within the multi-subunit 
core (Fig.  1b). The mechanism that explains the ability 
of these proteins to provide the catalytic activity of the 
B-L-100 subcomplex is unknown at this time [35], but 
earlier work has shown that FANCL and FANCB are 
required for the nuclear localization of FANCA, sug-
gesting that at least one role of the catalytic core subu-
nit functions to ensure proper assembly of the entire FA 
core [39]. The A-G-20 and B-L-100 subcomplexes form 
around FANCM once localized to the nucleus where they 
are both stabilized by FANCF, allowing for the formation 
of the entire core complex that is able to direct FANCL 
to FANCD2–FANCI for monoubiquitination [39]. The 
phosphorylation of FANCA on Serine 1449 in a DNA-
damage inducible manner is dependent on ATR and has 
also been shown to promote FANCD2–FANCI mon-
oubiquitination and downstream FA pathway function 
through a mechanism yet to be elucidated [40].
Ubiquitinated FANCD2–FANCI is required for its own 
recruitment to the ICL site, as well as for the promotion 
of the nucleolytic incision flanking the crosslink [22]. The 
exact components and mechanism surrounding the endo-
nucleolytic cleavage of an ICL is not yet clear, however it 
has been shown that XPF–ERCC1, MUS81–EME1, FAN1, 
and/or SNM1 are necessary for ICL incision, which helps 
to facilitate unhooking of the structure [26, 38, 41–53]. It 
has also been recently shown that the SLX4 scaffolding 
protein forms a complex with XPF–ERCC1 to stimulate its 
fork unhooking activity [54]. An unidentified translesion 
polymerase inserts a base opposite the unhooked lesion 
in order for bypass to occur on the leading strand [26]. 
MUS81–EME1 then processes the stalled replication fork 
on the lagging strand into a double stranded break, serving 
as a programmed intermediate [43]. The leading strand is 
then extended by the Rev1–pol ζ complex [55] and ligated 
to the first downstream Okazaki fragment which further 
functions as a template for repair of the double stranded 
break, incurred on the lagging strand, through homologous 
recombination [56]. In the case of proper ICL repair by the 
FA pathway, the lesion is repaired in a timely manner while 
maintaining the fidelity of the genetic code where it had 
originally interfered. In the absence of one of the key com-
ponents of the FA mediated pathway of ICL repair, aberrant 
end joining results in radial chromosome formation that is 
characteristic of Fanconi anemia cells [34, 57].
Repair pathway choice
There is evidence to show that the FA pathway may 
have a role in preventing chromosomal instability by 
determining the repair pathway choice that occurs at 
the DSB generated during ICL repair. Inappropriate 
nonhomologous end joining (NHEJ) results in the liga-
tion of free DNA ends that could originate from differ-
ing locations, making it responsible for the translocations 
observed in FA deficient cells. Interestingly, knockout 
of factors necessary for NHEJ alleviates much of the 
interstrand crosslink sensitivity observed in FA cells, 
demonstrating that one of the critical roles of Fanconi 
anemia proteins is the suppression of aberrant end join-
ing that leads to chromosomal instability [58]. It has 
been reported that Ub-FANCD2 promotes HR and 
represses NHEJ by localizing histone acetylase TIP60 to 
the damaged chromatin, which then acetylates H4K16 
and effectively blocks binding of 53BP1 to the neigh-
boring dimethylated histone H4K20 (H4K20Me2) [59]. 
53BP1 association with H4K20Me2 blocks end resection, 
the initiating event of HR, allowing NHEJ to proceed 
as the method of repair [59]. Ub-FANCD2 is required 
for impeding the ability of 53BP1 to promote NHEJ so 
that HR can faithfully restore the damaged genomic 
sequence. Additionally, the resection-promoting protein 
CtIP has been shown to interact with monoubiquitinated 
FANCD2. This interaction allows for end resection of the 
exposed strands during double stranded breaks, which 
is the committal step in promoting a homology directed 
repair pathway over error-prone end joining. The ability 
for Ub-FANCD2 to mediate CtIP end resection shows 
that the FA pathway is required for initiating the faithful 
repair at a double stranded DNA break [60].
Promotion of replication fork stability
Fanconi anemia deficient cells have an impaired ability 
to restart replication at collapsed forks resulting from 
encounters with crosslinking lesions and DSBs [61]. 
Additionally, depletion of FANCA or FANCD2 causes 
DSB accumulation during normal replication, indica-
tive of prolonged replication fork stalling [62]. Although 
evidence existed to support the ability of the FA path-
way to stabilize replication forks, it was not until recently 
that the elucidation of its interaction with FAN1 began 
to provide an explanation for how FA proteins accom-
plish this mechanistically. It has now been discovered 
that replication fork stability is achieved through the 
recruitment of FAN1 to stalled forks in an Ub-FANCD2 
dependent manner [63]. FAN1 has been shown to inter-
act with FANCD2 through its N-terminal UBZ binding 
domain, and has structure specific exonuclease activity 
with 5′ flaps as a preferred substrate [64]. Mutations in 
FAN1 are associated with ICL sensitivity and chromo-
some instability. However, the disease in FAN1-mutated 
individuals present as Karyomegalic Insterstitial Nephri-
tis rather than Fanconi anemia. This differing phenotypic 
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manifestation could indicate that FAN1 may have a sec-
ondary role in resolving ICLs, but its primary function is 
not limited to this [64, 65]. Consistent with this explana-
tion, the recruitment of FAN1 by Ub-FANCD2 has been 
shown to be necessary for protecting stalled replication 
forks even in the absence of ICLs, although the mecha-
nism of action for this protective ability is unknown. 
Also, FAN1 is not required for ICL repair, but still col-
laborates with FANCD2 to prevent replication forks from 
progressing when stalled at sites of DNA damage [63], 
a function that is required for preventing chromosomal 
instability. The abilities of the FA pathway in remediat-
ing replication dysfunction through recruitment of repair 
proteins, such as FAN1, underline its essential role in 
preventing aberrant processing of DNA lesions encoun-
tered by the replication machinery.
Fanconi anemia pathway and Bloom helicase
Another interesting FA-mediated mechanism of genome 
maintenance involves the interaction of Ub-FANCD2 
and Bloom helicase (BLM) and their co-localization to 
the nucleus when replication forks stall. BLM is mutated 
in Bloom syndrome, an inherited genomic instability dis-
order similar to Fanconi anemia in its childhood cancer 
predisposition as well as the presence of aberrant chro-
mosome structures [66]. Earlier work has shown that 
a BLM complex, consisting of BLM, RMI1, RMI2, and 
TopoIIIα, associates with 5 of the FA (-A, -C, -E, -F, -G) 
proteins to form an even larger complex termed BRAFT, 
which displays helicase activity dependent on BLM [67]. 
Later it was shown that the association of the BLM com-
plex with FA core proteins (FANCA, FANCE, FANCF) 
is mediated by a mutual interaction with FANCM where 
FANCM acts as a link between the two complexes [68]. 
This protein–protein interaction between FANCM and 
the BLM/FA complexes is required for resistance to 
MMC sensitivity as well as for foci formation at stalled 
replication forks [68]. Most recently it has been dis-
covered that motif VI of BLM’s RecQ helicase domain 
contributes to regulation of the activation of FANCD2. 
Evidence for this was shown in U2OS cells with BLM 
knocked down via shRNA and then transfected with an 
expression plasmid containing mutations in motif VI that 
have also been documented to occur in certain cases of 
human cancer. Results from this transfection showed that 
deletions and point mutations within region Y974Q975 of 
BLM motif VI caused FANCD2 activation to be compro-
mised after UVB treatment. Additionally, a proliferation 
assay showed reduced survival in mutant motif VI-trans-
fected U2OS cells upon UVB and MMC treatment [69]. 
Together, these separate studies corroborate a collabora-
tive effort for BLM and FA pathways in response to rep-
lication stress, although the exact function carried out 
through this interaction in replication-associated repair 
seems to remain largely a mystery. It appears that BLM is 
responsible for elevated sister chromatid exchange (SCE) 
independently of the FA pathway, but BLM does assist FA 
proteins in ICL repair [70]. BLM has shown the ability to 
resolve holiday junction structures during HR, and FA 
proteins have demonstrated their own roles in facilitating 
HR [71], possibly indicating that the functional interac-
tion between these two complexes relates to maintenance 
of HR events that take place at the DSB that is produced 
during ICL removal. There are many missing pieces to 
the puzzle of the relationship between the BLM and FA 
pathways; more research is needed to fully detail the 
events that characterize BRAFT and the conditions that 
require BLM and FA proteins to work together.
Coordination of the alternative end‑joining pathway 
of repair
A study has confirmed a role of the FA pathway in sup-
porting the Alt-EJ method of repair in cancers with 
BRCA1 or BRCA2 deficiencies. Alt-EJ is not a commonly 
utilized repair pathway in normal cells, but is thought 
to be responsible for translocations resulting in severe 
genomic instability observed frequently in cancer. Alt-EJ 
has been proposed as a culprit for these genomic rear-
rangements due to the sequences of microhomology that 
are present at chromosomal break-point fusion sites that 
are also characteristic of the microhomology sequences 
thought to mediate the ligation step in the microhomol-
ogy mediated end joining (MMEJ) subtype of Alt-EJ [72]. 
Alt-EJ is proposed as an alternative to C-NHEJ making 
it primarily active during G1, although it can serve as an 
alternative repair mechanism to homologous recombina-
tion in S phase as well [72]. While the reasons that the 
extremely deleterious Alt-EJ undertakes repair of DSB 
in the place of HR or NHEJ is still heavily debated, it has 
been proposed to arise as a backup mechanism that takes 
place in cases when other pathways, such as HR and 
NHEJ, cannot be carried out [73]. BRCA1/2 cancers have 
been shown to rely on Alt-EJ for stabilization of replica-
tion forks and DSB repair in the absence of functional 
HR. The promotion of Alt-EJ in place of HR allows for 
survival of these cancers when faced with cytotoxic DNA 
damage and replicative stress perpetuated by a genomic 
instability phenotype. Examination of FANCD2 during 
DNA repair events in BRCA1/2 tumors has revealed its 
ability to recruit Pol θ and CtIP, factors that are critical 
for the Alt-EJ pathway. Monoubiquitination of FANCD2 
was shown to be required for its coordination of these 
essential Alt-EJ components. FANCD2 also stabilizes 
stalled replication forks in BRCA1/2 deficient cancers, 
permitting their viability in extremely unstable genetic 
conditions [74]. Not only does this discovery establish 
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a role for FANCD2 in promoting the error-prone Alt-EJ 
pathway, but also reveals the possibility of the FA path-
way proteins serving as potent therapeutic targets in HR-
defective malignancies.
R‑loop resolution
Another example of FA canonical function involves the 
resolution of replication forks that are blocked by tran-
scription intermediates such as R-loops. R-loops are 
extremely stable, 3-stranded RNA:DNA hybrids gener-
ated by RNA Polymerase during transcription and serve 
as a source of genomic instability. They have physiologi-
cal relevance in cellular processes such as class-switch 
recombination and mitochondrial DNA replication, 
but are also rare transcription events capable of caus-
ing altered gene expression and replication fork stall-
ing when they encounter the replication machinery [75, 
76]. Although the exact mechanism of R-loop induced 
genomic instability is not entirely known, they may 
induce harmful chromatin condensation capable of erro-
neously silencing gene expression [77]. Their elimina-
tion is necessary for maintaining faithful replication by 
preventing collision with replication machinery in addi-
tion to preventing faulty heterochromatin formation. 
Evidence for the FA pathway’s ability to facilitate R-loop 
removal is seen by the persistent R-loop accumulation 
in FANCD2 and FANCA depleted cells [78]. RNA:DNA 
hybrids are known substrates for RNase H1 and treat-
ment of FANCA−/− lymphoblast patient cell lines with 
RNase H1 reduces FANCD2 nuclear foci accumulation 
[78]. Another study has shown that FANCD2 monoubiq-
uitination and foci formation was significantly reduced 
upon treatment with a transcription inhibitor. This sup-
ports the idea that a transcription intermediate, likely 
an R-loop, is responsible for activating the FA pathway 
to participate in repair [79]. Although the monoubiquit-
ination of FANCD2 does indicate that the canonical FA 
pathway is involved in R-loop removal, the role of how 
this pathway regulates R-loop accumulation is not com-
pletely clear. The exact proteins that fulfill many aspects 
of this process remain to be identified, but the individual 
properties of some FA proteins would make them excel-
lent candidate genes. Recognition of the R-loop struc-
ture, for example, could be carried out by FANCA, which 
has been shown to have RNA binding activity [37].
Role of FANCA in maintaining genomic stability
Mutations in any of the 21 complementation groups 
cause an affected individual to present the standard 
phenotypes associated with Fanconi anemia. However, 
FANCA is found to be responsible for approximately 
64% of FA cases [80–83] which raises great curiosity 
about the potential significance this protein may hold 
in maintenance of genome integrity. As seen in patients 
carrying mutant FANCA, even different patient muta-
tions within the same protein can have varying pheno-
types. FANCA patient studies revealed that a monoallelic 
delE12–31 mutation was associated with higher rates 
of AML or MDS as well as anatomic malformations not 
observed in other FANCA mutations [84]. Some patient-
derived FANCA mutants still show the ability to mon-
oubiquitinate FANCD2, albeit at lower levels, yet still 
display characteristic FA phenotypes and disease pro-
gression [85]. FANCA is emerging as a more interest-
ing protein than previously evaluated due to its recently 
elucidated biochemical properties that are implicated in 
overcoming multiple forms of replication stress, as well 
as promoting different pathways of DNA repair.
FANCA contains 1455aa with a molecular weight 
of 163  kDa. It has a leucine zipper-like motif between 
amino acids 1069 and 1090 [86] and a bipartite Nuclear 
Localization Signal in its N-term that is activated by 
direct binding with FANCG [87] (Fig. 2). Disease-causing 
mutations are mostly found in the C-terminal, which has 
been shown to be required for the DNA binding function 
of FANCA [37]. While much still remains to be discov-
ered about the biochemical properties of FANCA, recent 
research has uncovered some very interesting functions 
of this protein separate from its role in the canonical FA 
pathway. Due to its increasing importance in genome 
preservation, the following section will specially focus on 
the roles of FA proteins in maintaining genomic stabil-
ity through absolving replicative, oxidative, and mitotic 
stress.
Regulations of MUS81–EME1 endonuclease activity 
by FANCA
Our lab has shown the ability of FANCA to mediate the 
incision step of ICL repair by regulating MUS81–EME1 
in  vitro [38]. MUS81–EME1 is a structure specific het-
erodimeric endonuclease complex with substrate prefer-
ence for 3′ flap structures with a 5′ end 4 nucleotides away 
from the flap junction [88]. We have also demonstrated 
that MUS81–EME1 was able to cleave the 5′ leading 
strand at the site of an ICL, 4–5 nucleotides away from 
the junction site [38]. FANCA regulates cleavage activity 
of MUS81–EME1 by recruiting the heterodimer when a 
verified ICL is present at the site of replication fork stall-
ing, or FANCA will inhibit MUS81–EME1 accumulation 
in the case of non-ICL damage [38]. FANCA protects 
the genome in this manner by preventing MUS81–
EME1 from creating unnecessary double strand breaks. 
Interestingly, a different in vivo study showed increased 
cases of embryonic lethality in FANCC/MUS81 double 
knockout mice. FancC(−/−)/Mus81(−/−) mice also dis-
played developmental abnormalities, such as craniofacial 
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malformations and ocular defects, that mimic human FA 
patient phenotypes and are not recapitulated in mouse 
disease models carrying FA mutations alone [89]. This 
could suggest that other FA proteins, in addition to 
FANCA, participate in the regulation of MUS81–EME1 
in its roles of ICL repair and holiday junction (HJ) reso-
lution. Some of the phenotypes of FA patients could be 
attributed to a combination of defective ICL repair and 
HJ resolution, accounting for at least some of the broad 
range of symptoms ranging from pancytopenia to short 
stature and developmental delays [89].
FANCA/XPF/Alpha II Spectrin interaction
Earlier work has shown that FANCA interacts with XPF 
and Alpha II Spectrin (aIISP) and that these three pro-
teins co-localize to the nucleus in the case of ICL dam-
age [90]. Because XPF has the ability to perform the 
dual incision step at the 5′ and 3′ locations flanking an 
ICL [91], it can be postulated that FANCA is at least par-
tially responsible for coordinating and regulating this 
critical repair step in order to ensure ICL removal. This 
claim is further substantiated by the observation that 
FANCA(−/−) cells are defective in this ICL dual incision 
step [92], suggesting that FANCA function is essential 
for the removal of these bulky lesions in order to main-
tain the integrity of the genetic code that they obstruct. 
It has been proposed that XPF–ERCC1 is the primary 
nuclease responsible for the unhooking step of ICL 
removal and that MUS81–EME1 plays a backup role in 
instances where XPF–ERCC1 is unable to perform its 
function. This has been speculated due to reduced sensi-
tivity of MUS81–EME1 to crosslinking agents compared 
with XPF–ERCC1 deficient cells. MUS81–EME1 could 
also act during very specific instances of replication fork 
blockage that produce substrates for which it has prefer-
ence, as in certain cases where the ICL is traversed and 
leading strand synthesis creates a 5′ flap on the 3′ side 
of an ICL [88]. Again, FANCA may serve as the regula-
tory component of these nuclease arrangements during 
ICL repair by determining which nuclease is required 
depending on the substrate present, and then subse-
quently recruiting or stimulating activity of the proper 
enzyme.
The potential significance of the interaction between 
FANCA and αIISP should not be ignored. αIISp is well 
known as a structural protein that associates with the 
nuclear matrix [93]. Previous work has suggested that the 
nuclear matrix may have a role in DNA damage repair, 
supported by the localization and assembly of NER fac-
tors to the nuclear matrix that is induced upon UV 
irradiation [94, 95]. Because XPF–ERCC1 is required 
for NER [96] and has also been shown to co-immuno-
precipitate with FANCA and αIISp [90], it is likely that 
the repair activities facilitated by the nuclear matrix are 
important for genome maintenance in FA mediated path-
ways as well. It is proposed that αIISp acts as a scaffold 
to ensure proper assembly and alignment of ICL repair 
factors FANCA and XPF–ERCC1 during the incision 
step. Consistent with this, αIISp binds to DNA contain-
ing ICL damage and enhances the dual incision activity 
at these lesions. Additionally, FANCA, FANCB, FANCC, 
and FANCD2 deficient cells all exhibit lower αIISp lev-
els, which results in reduced ICL repair compared with 
normal cells [97]. It appears that the relationship between 
FANCA and αIISp is important for increasing the effi-
ciency of the ICL incision performed by XPF–ERCC1, 
perhaps through association with the nuclear matrix. It 
has been shown that FANCA and FANCC also form a 
complex with αIISp [98], yet the establishment of a role 
for the FA core or FA subcomplexes in the mechanism 
of αIISp related DDR (DNA damage response) remains 
to be defined. It has been discovered, however, that the 
Fig. 2 Structure and functional annotation of FANCA (NP-000126). The intrinsic nucleic acid binding activity resides in the C-terminal domain 720–
1455. The N terminus contains the nuclear localization signal (18–34 or 19–35) [164] and was found crucial for both FANCG and FANCC interactions. 
The region 740–1083 mediates the interaction with BRCA1. Other putative functional remarks include a peroxidase (274–285), a PCNA interaction 
(1128–1135) motif, and a partial leucine zipper (1069–1090). Proteomic evaluation reveals multiple phosphor serine on FANCA, among which S1149 
and S1449 were characterized as AKT and ATR substrates and critical for FANCA functions
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regulation and stabilization of αIISp levels by FANCA 
[99] allows for another level of chromosomal mainte-
nance. It has been shown that knockdown of αIISp lev-
els to those present in FANCA deficient cells (35–40%) 
leads to a fivefold increase in chromosomal aberrations 
such as radials, breaks, and intrachromatid exchanges 
[100]. This indicates that regulation of αIISp by FA pro-
teins is protective against chromosomal damage result-
ing from improperly processed ICL’s. Further research 
has revealed that the binding of FANCA and FANCG 
to the SH3 domain of αIISp prevents its degradation by 
μ-calpain, a protease that cleaves αIISp at Tyr1176 within 
repeat 11 [101, 102]. This inhibition is accomplished by 
blocking low-molecular-weight phosphotyrosine phos-
phatase (LMW-PTP) from dephosphorylating Tyr1176 
and creating the available cleavage site for μ-calpain. 
FANCA and FANCG are also able to bind to μ-calpain, 
preventing its cleavage activity and allowing normal 
levels of αIISp to persist and carry out its functions in 
DNA repair. The loss of any of the FA proteins capable 
of blocking μ-calpain cleavage would then cause overac-
tive breakdown of αIISp resulting in chromosomal insta-
bility. So far only FANCA and FANCG have been shown 
to physically interact with the SH3 domain of αIISp, but 
excess cleavage products of αIISp have been observed in 
FA-C, FA-D2, and FA-F cells so far [102]. The discovery 
of a DNA damage repair role for αIISp contributes to 
the elucidation of the full sequence of events that occur 
during resolution of ICL lesions. The proposed ability of 
αIISp to act as a scaffolding protein to promote incision 
activity also supports the individualized role of FANCA 
in mediating ICL removal along with XPF, although more 
work must be done in order to establish if, when, and 
how other FA proteins contribute to this process.
FANCA/FEN1 interaction
FANCA has also been shown to stimulate the flap endo-
nuclease activity of FEN1 with both 5′RNA flaps and 
DNA flaps as substrates [103]. FEN1 interacts with over 
30 other proteins and is active in Okazaki fragment matu-
ration, telomere maintenance, and replication fork rescue 
[104]. These functions and its aberrant expression in ade-
nocarcinomas and other cancers have contributed to the 
general acceptance of FEN1 as a tumor suppressor gene. 
The interaction of FANCA with FEN1 could implicate a 
direct role in correct processing of Okazaki fragments. 
It is also possible that FANCA may work in concert with 
FEN1 in lagging strand synthesis through stabilization of 
the replication machinery while ensuring accurate copy 
of genetic information contained within Okazaki frag-
ments. This is supported by co-localization of FANCA 
to replication forks in the absence of DNA damage [38, 
103]. FANCA increases the efficiency of FEN1, possibly 
by loading it onto its substrate or competing for binding 
with its substrate, which could be responsible for increas-
ing its turnover rate. It is possible that FANCA and FEN1 
interact with each other in multiple processes due to the 
fact that FEN1 is stimulated by MUS81–EME1 in ICL 
unhooking and HJ resolution [105], two activities that 
FANCA has been proposed to participate in. Addition-
ally, FANCA and FEN1 are both known to stabilize repli-
cation forks so it is likely that the two may work together 
in achieving this function.
FANCA as a factor in resection‑mediated repair pathways
FANCA has also shown itself to be an important fac-
tor for resection-mediated repair pathways. FANCA 
promotes homologous recombination as observed in a 
threefold reduction of GFP-positive FANCA null fibro-
blasts in an I-SceI based reporter assay that restores 
expression of GFP at a DSB site when repaired by HR 
[106]. FANCA could be supporting the homologous 
recombination route of repair through its interaction 
with BRCA1 via its N-terminal region [107], perhaps 
by recruiting, stabilizing or stimulating its activity as 
the role of this interaction is not clear in the context of 
DSB repair. It is not yet known whether promotion of 
HR involves other core complex proteins or not. In a 
similar assay, FANCA was also shown to be important 
in the single-stranded annealing pathway of repair (SSA) 
as seen by an approximate 50% decrease in SSA repair 
products at an I-SceI induced DSB in FANCA null fibro-
blasts [106]. This could be the result of FANCA’s role in a 
mechanism common to all modes of homology directed 
repair, or FANCA could specifically promote SSA under 
certain circumstances. The two main proteins known 
to mediate SSA are RAD52, which catalyzes the anneal-
ing step between homologous regions on resected ends 
at DSB; and RAD59 stimulates the annealing activity of 
RAD52 [107]. A direct interaction between FANCA and 
either of these two SSA proteins has yet to be shown, 
leaving much to be discovered about the actual activity 
carried out by FANCA in this repair pathway. Interest-
ingly, studies have shown that XPF/ERCC1 functions as 
the flap endonuclease that removes the single-stranded 
non-homologous flaps generated from the formation 
of recombination intermediates during SSA [108, 109]. 
Because both FANCA and XPF/ERCC1 promote SSA 
and have been shown to co-localize in nuclear foci during 
ICL repair [90], perhaps the two carry out a comparable 
function when the SSA pathway takes place at a double-
ended DSB. As mentioned previously, the ability of XPF 
to create incisions at an ICL lesion is defective in the 
absence of FANCA [92], indicating a stimulatory effect 
of FANCA on the nuclease activity of XPF. Therefore, it 
is feasible that FANCA interacts with XPF/ERCC1 in a 
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similar manner during the flap removal step that follows 
annealing of homologous regions during SSA. Future 
studies will be required to discover exactly how FANCA 
participates in SSA and which proteins it interacts with in 
this repair process. More work also needs to be done to 
assess the conditions that regulate SSA activity because it 
is an error-prone pathway that must be tightly controlled 
in order to prevent dangerous genomic deletions.
It has also been recently discovered that FANCA par-
ticipates in the alternative end-joining (Alt-EJ) method of 
DNA repair [110]. The previously referenced I-SceI/GFP 
reporter assay has shown that depletion of FANCA using 
SiRNA significantly decreased the amount of observed 
Alt-EJ in U2OS cells, while FANCA expression in mEF 
null cells increased the amount of repair product result-
ing from Alt-EJ [110]. This result may not have to do with 
individual FANCA activity itself, but rather the ability 
of the FA core complex to suppress NHEJ, which would 
allow Alt-EJ to occur. Support for this comes from the 
knockdown of other FANC proteins that displayed simi-
lar results as the FANCA knockdown. Although FANCA 
may promote Alt-EJ, Alt-EJ is not entirely dependent on 
FANCA because in FANCA null mEF (mouse embryonic 
fibroblast), Alt-EJ does still occur and is even increased 
by the further knockout of NHEJ factor Ku70 [110]. On 
the other hand, FANCA has shown the ability to stabilize 
regions of microhomology during Ig class switch recom-
bination in B cells, which may translate to the ability of 
FANCA to recognize and stabilize duplexes throughout 
the genome during other processes mediated by micro-
homology such as Alt-EJ [111]. This could suggest a role 
for FANCA in promoting Alt-EJ without being entirely 
necessary for the pathway.
FANCA could also potentially be involved in the 
recruitment of other repair factors that promote the 
downstream steps of this pathway, such as the endonu-
cleases that remove flap substrates resulting from het-
erologous tails that surround the homologous regions. 
An official flap-removal endonuclease has not yet 
been assigned to the Alt-EJ pathway. The XPF–ERCC1 
homolog Rad1–Rad10 is able to cleave such heterologous 
tails in yeast, but the loss of XPF–ERCC1 does not cause 
a major decrease in Alt-EJ [112], which could mean that 
an additional protein is capable of carrying out this step. 
FANCA is able to regulate the catalytic activity of FEN1 
[103] which has already been shown to contribute to Alt-
EJ [113] and could feasibly act on the 5′ heterologous 
flaps resulting from the annealing step that are consist-
ent with the structure-specific substrates on which FEN1 
acts. Determining the factors that promote high-fidelity 
pathways of repair as opposed to error-prone mecha-
nisms provide great insight into the conditions that per-
mit the persistence of genome instability.
Fanconi anemia proteins in mitigating oxidative 
stress
Reactive oxygen species (ROS) are a known source of 
DNA damage that can drive genomic instability. ROS 
such as hydroxyl radicals (OH·) can cause damage to 
all four nucleotide bases, and 1O2 can react with gua-
nine producing carcinogenic alterations to DNA in the 
forms of mismatched bases, insertions, deletions, rear-
rangements, and chromosomal translocations charac-
teristic of cancer-driving chromosomal instability [114]. 
8-hydroxyguanine (8-OHG) or 8-oxo-2′-deoxyguanosine 
(8-oxo-dg) is the most commonly observed alteration 
resulting from ROS and the levels of these lesions are 
used to evaluate the amount of DNA damage occurring 
as a result of oxidative stress [114, 115]. Endogenous ROS 
are produced from the electron transport chain of mito-
chondria, lipid metabolism, and inflammatory cytokines 
while exogenous ROS can arise from ionizing radia-
tion [116]. Damage from ROS occurring within a gene 
that is required for maintenance of genomic stability 
can effectively silence a tumor suppressor or other pro-
tein involved in DNA damage repair. ROS can also cause 
single or double-strand breaks of the DNA back bone, 
which can lead to loss of essential genetic information if 
not properly repaired [117]. An excess of DNA damage 
caused by ROS triggers p53 mediated apoptosis, and high 
levels of induced-cell death can lead to increased prolif-
eration in order to replace the lost cells. This increased 
proliferation can provide a selective pressure for cells to 
evade apoptosis, which then results in genome instabil-
ity and clonal selection of cells that harbor pro-oncogenic 
mutations [118].
Evidence of FA proteins in regulating cellular oxidative 
stress
Disulphide linkage of FANCA and FANCG is induced 
concurrently with FANCD2 monoubiquitination in cells 
experiencing increased oxidative conditions, indicating a 
function for the FA pathway in responding to a harmful 
cellular environment caused by oxidative damage [119]. 
FA cells of differing complementation groups have also 
been shown to be hypersensitive to treatment with H2O2, 
a major source of ROS [119]. Signs of hypersensitiv-
ity range from elevated levels of 8-OHG in FANCC and 
FANCE deficient cell lines [120] to increased apoptosis in 
FANCA and FANCC deficient cells in pro-oxidant con-
ditions [120, 121]. Although it may be true that FA pro-
teins control oxidative DNA damage by participating in 
the repair of DNA lesions caused by ROS, there is also 
strong evidence that FA proteins are directly involved 
in regulating the amount of ROS and resulting oxida-
tive DNA damage that persists within a cell. FA cells 
from groups A, C, and D2 display high levels of ROS and 
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changes in mitochondria morphology that affect its roles 
in ATP synthesis and oxygen reuptake [122]. These mis-
shapen mitochondria are then unable to produce ROS 
detoxifying enzymes such as Super Oxide Dismutase 
(SOD1), further allowing excess levels of ROS to accu-
mulate [122]. Additionally, repair enzymes that function 
in the resolution of stalled replication forks can contrib-
ute to elevated levels of ROS that damage mitochon-
dria, creating a vicious cycle of mitochondrial structural 
damage that results in unbridled ROS persistence [123]. 
The presence of excess ROS might also be a contribut-
ing factor to the cytoxicity of crosslinking agents in the 
case of FA deficiency. Support for this is shown by the 
ability for ROS scavengers, such as N-acetyl-1-cysteine 
(NAC), to ameliorate MMC sensitivity in FA cells [123]. 
Consistent with this claim, crosslinking agent DEB is able 
to induce oxidative DNA damage in the form of 8-OH-
dG and the repair of DNA damage caused by DEB is 
dependent on antioxidant genes glutathione S-trans-
ferase (GST) and GSH peroxidase (GPx) [124]. Another 
source of ROS in FA cells stems from the overproduc-
tion of TNF-alpha and its direct effects on mitochon-
dria, as well as its JNK-dependent ability to generate 
ROS through a positive feedback loop mechanism [125, 
126]. The hypersensitivity of FANCC cells to TNF-alpha 
has been shown to cause increased apoptosis resulting 
in the clonal evolution that leads to AML. Restoration 
of FANCC expression protected cells from clonal evolu-
tion, while preventing excess ROS in these cells delayed 
leukemia development [127]. Sensitivity of overexpressed 
TNF-alpha and the increased ROS that it causes contrib-
utes to the genetic instability that leads to hematological 
malignancies in FA patients. The ability for ROS accumu-
lation to exacerbate conditions already known to require 
FA protein intervention could at least partially explain 
the phenotypes observed in FA patients that are not pre-
sent in diseases resulting from deficiencies in DNA repair 
proteins that function in similar pathways.
Multiple studies have confirmed biochemical activi-
ties of FA proteins in regulating the levels and damaging 
effects of ROS. The first evidence of direct FA protein 
capabilities in maintenance of cellular redox homeosta-
sis came from the discovery of the interaction between 
FANCC and Cytochrome P450, a key enzyme in oxida-
tive metabolism [128]. It was later found that FANCG 
interacts with cytochrome P4502E1 (CYP2E1), support-
ing direct roles for multiple FA proteins in redox metabo-
lism [129]. Further research has found that H2O2 induces 
monoubiquitination of FANCD2, showing that the entire 
FA pathway is involved in an oxidative stress response, 
and also explaining the observed ROS sensitivity associ-
ated with mutations in complementation groups com-
prising the core complex [125].
Protection of antioxidant gene promoters by the FA 
pathway
An interesting mechanism of FA proteins, specifically 
FANCA, in preventing cells from accumulation of ROS 
involves the protection of antioxidant gene promot-
ers from oxidative stress [130]. DNA damage caused by 
ROS occurs selectively in promoter regions of several 
antioxidant genes such as GCLC, TXNRD1, GSTP1 and 
GPX1 in FA bone marrow (BM) cells, effectively down-
regulating these protective cellular components, and 
contributing to the elevated levels of ROS observed in FA 
cells. 8-oxo-dG was the most common lesion observed, 
which is known to be highly mutagenic and capable of 
causing harmful transversions to genomic DNA. It was 
found that FANCA association with BRG1, the ATPase 
subunit of the BAF subcomplex in chromatin remod-
eling, greatly reduced the amount of oxidative damage to 
antioxidant promoters (GPX1 and TXNRD1) compared 
with FA-A cells [130]. BRG1-FANCA mediated reduc-
tion in promoter oxidative damage was also dependent 
on monoubiquitinated FANCD2. In summary, FANCD2 
activation of the FANCA-BRG1 complex is necessary for 
protection of oxidized bases in promoter regions of anti-
oxidant genes through a type of chromatin remodeling 
activity [130].
Ub‑FANCD2 prevents TNF‑alpha overexpression
FA cells are also deficient in neutralizing superoxide ani-
ons produced by elevated TNF-alpha levels [125]. The 
explanation for excess TNF-alpha levels in FA cells lies in 
the ability of the FA pathway to prevent NF-kB-mediated 
gene expression. The NF-kB transcription factor is able 
to up-regulate TNF-alpha levels through binding to the 
kB1 consensus site present in the TNF-alpha promoter 
region [131]. It has been shown that monoubiquitinated 
FANCD2 is able to functionally repress NF-kB transcrip-
tional activity by binding to its kB1 consensus sequence 
within the distal site of the TNF-alpha promoter. The 
loss of inhibition of NF-kB induced gene expression 
allows unchecked TNF-alpha production that further 
generates harmful ROS. Activation of FANCD2 through 
monoubiquitination is required for its recruitment to 
the TNF-alpha promoter, but not for recognition of the 
NF-kB consensus site [125]. Additionally, FANCD2 defi-
ciency allows for the overexpression of TNF-alpha that is 
observed in FA patients by allowing histone acetylation 
of the TNF-alpha promoter. The absence of FANCD2 
results in increased apoptosis and high levels of DNA-
damaging ROS [132]. The FANCD2 protein itself regu-
lates ROS through a chromatin remodeling mechanism 
that allows for the deacetylation of histones within the 
TNF-alpha promoter in a monoubiquitination-inde-
pendent manner [132]. The multiple roles of FA proteins 
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in regulating the cellular oxidative state demonstrate 
the versatility of functions that they are able to utilize in 
order to protect the genome.
Mitotic roles of Fanconi anemia proteins
Mitotic stress is a major contributor to genomic insta-
bility and cancer progression. The ability of cells to suc-
cessfully segregate chromosomes and divide properly is 
equally essential to genomic integrity as proper genomic 
DNA replication. Aneuploidy is often present in solid 
tumors, and results from chromosome instability that 
usually stems from chromosome mis-segregation [133]. 
Mutated or aberrantly expressed proteins that participate 
in any of the tightly regulated steps conducting mitosis 
can cause chromosome instability. One of the features of 
Fanconi anemia cells across all disease mutations is the 
presence of aneuploidy and micronucleation, implicating 
a role for these proteins in ensuring faithful chromosome 
segregation.
The FA/BLM relationship prevents aberrant chromosomal 
structures
One of the ways that the FA pathway prevents chro-
mosome instability is by linking the recognition of 
replication stress to the resolution of chromosome 
abnormalities in mitosis through interaction with BLM 
[134]. Micronucleation occurs in FA cells during aphidi-
colin (APH) treatment, a drug that induces ultra-fine 
bridges (UFB) at common fragile sites (CFS), also known 
as difficult-to-replicate regions. Commonalities among 
the various CFSs have been difficult to decipher, but they 
are generally classified as ‘hot spots’ of genome instability 
where chromosome breakage and aberrant fusions fre-
quently occur, and are often responsible for loss of tumor 
suppressors and oncogene amplifications [135, 136]. Ear-
lier research has shown that cells with a disrupted FA 
pathway exhibit a two to threefold increase in chromo-
some breaks at known CFSs FRA3B and FRA16D, indi-
cating the involvement of the FA pathway in maintaining 
the stability of these regions [137]. Functional FA path-
way expression in fibroblasts has further been shown to 
rescue micronucleation caused by UFB at these CFSs, 
when compared with FA deficient fibroblasts [134]. 
The FA pathway has shown the ability to facilitate BLM 
repair function at anaphase bridges and faulty replica-
tion intermediates [134]. Anaphase bridges and UFBs are 
the structures that connect two daughter nuclei in rep-
licating cells whose chromosomal DNA fails to separate, 
resulting in micronuclei and aneuploidy [138]. BLM has 
been shown to localize to these DNA-bridge structures 
and suppress their formation in normal cells [139]. The 
FA pathway has already demonstrated a common role 
with BLM in resolving replication stress, but there is 
also evidence to support that the FA/BLM relationship 
extends into mitotic genome maintenance as well. Confo-
cal microscopy images have shown BLM bridges in nor-
mal cells connecting spots on segregating chromosomes 
where FANCD2 is located, and the amount of these BLM 
bridges increased upon APH or MMC treatment. Further 
analysis of the interaction between BLM and FANCD2 
during mitosis revealed that BLM localization to non-
centromeric anaphase bridges is compromised in FANC 
deficient cells, suggesting that the FA pathway is required 
for recruitment and/or stabilization of BLM at these 
APH-induced DNA structures [134] These capabilities 
indicate a role for the FA pathway in preventing mis-
segregation of chromosomes when DNA lesions capable 
of compromising replication persist. It also further illus-
trates how FA proteins are involved in maintaining CFSs 
both independently and through collaboration with BLM 
[137]. While the FA pathway plays a substantial part in 
reducing UFB persistence, the exact roles played by 
FANCD2–FANCI foci and its functional interaction with 
BLM in this mechanism remain to be elucidated. Most 
recently, it has been reported that FANCD2 prevents 
CFS instability and facilitates replication through CFSs 
by ameliorating DNA:RNA hybrid accumulation and by 
influencing dormant origin firing [140].
Proper regulation of the spindle assembly checkpoint 
by the FA pathway
The spindle assembly checkpoint (SAC) is responsi-
ble for coordinating proper destruction of sister chro-
matid cohesion and is able to halt the progression from 
metaphase to anaphase until appropriate kinetochore/
microtubule attachment is ensured [133]. The FANC 
proteins co-localize to the mitotic apparatus during M 
phase and mutations in FA genes cause multinucleation 
in response to the chemotherapeutic agent taxol, a drug 
that functions as a spindle poison by stabilizing micro-
tubules and disallowing them from attaching to kineto-
chores. The reintroduction of FANCA, specifically, is able 
to restore mitotic arrest and therefore SAC signaling in 
taxol-treated cells [141]. The FA proteins have also been 
shown to be partially responsible for maintaining cor-
rect centrosome numbers, confirmed by the presence of 
excess centrosomes upon pericentrin staining in primary 
patient-derived FA fibroblasts [141]. Abnormal centro-
some number contributes to aneuploidy and chromo-
some instability by causing merotely during kinetochore/
centrosome association, making centrosome mainte-
nance important for genomic stability [133].
Proper regulation of the SAC by FANCA
A more recent study confirmed that FANCA is crucial for 
regulating the SAC, and may play a more prominent role 
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in this upkeep than the other FA proteins. FANCA null 
cells are able to escape the SAC and apoptosis upon treat-
ment with taxol. In addition, FANCA proficient cells dem-
onstrated increased cell cycle arrest and cell death upon 
taxol treatment [142]. This ability could suggest a mecha-
nism by which an activated FANCA signaling pathway 
can prevent cancer in cells that do not satisfy the SAC by 
inducing apoptosis. Multinucleated cells were observed in 
FANCA KO cells upon treatment, indicating that a SAC 
compromised by loss of FANCA can cause chromosomal 
instability [142]. In the same study, FANCA demonstrated 
the ability to facilitate centrosome-mediated microtubule-
spindle formation and growth. It was discovered that 
centrosomes in FANCA null fibroblasts emanated less 
microtubules with FANCA+ cells, showing that FANCA 
manages correct microtubule length in spindle assembly 
[142]. It will be interesting to explore if other FA proteins 
assist FANCA in these activities or if FANCA performs its 
mitotic roles independently.
Mitotic protein interactions and roles of FANCA
Centrosome number and NEK2
The cytoplasmic activity of FANCA reinforces its poten-
tial to carry out individual functions in mitosis [143]. 
FANCA also likely has a distinct role in centrosome 
maintenance, supported by its localization to the centro-
some and its co-immunoprecipitation with gamma-tubu-
lin. Further support of a centrosomal role for FANCA 
comes from the discovery of its phosphorylation by 
NEK2 at threonine-351 (T351) [144]. FANCA’s interac-
tion with NEK2 is compelling due to the known ability 
of NEK2 in preserving centrosome integrity and its con-
tributions to carcinogenesis. NEK2 is up-regulated in a 
variety of cancers such as breast cancer and lymphoma 
and has already been recognized as a potential therapeu-
tic target for drug intervention [145]. More work must 
be done in order to establish the significance of the rela-
tionship between NEK2 and FANCA and the pathway in 
which they function, but this interaction does provide 
additional evidence to support centrosome maintenance 
activity for FANCA in centrosome maintenance. Consist-
ent with this, FANCA T351 mutants display abnormal 
centrosome numbers, and are sensitive to the microtu-
bule-interfering agent nocodazole. Correct centrosome 
number is important for ensuring faithful chromosome 
separation during cell division, which allows for genomic 
information to be properly passed down to daughter 
cells. In addition to sharing a common pathway with 
NEK2, siRNA knockdown of FANCA induces supernu-
merary centrosomes and mis-alignment of chromosomes 
during mitosis [144]. The evidence supporting FANCA 
regulation of centrosome number warrants further inves-
tigation into the mechanism of this function.
Chromosome alignment and CENP‑E
The N-terminus of FANCA directly interacts with the 
C-terminus of mitotic protein CENP-E [146]. CENP-E 
mediates microtubule/kinetochore attachments as well as 
chromosome congregation during mitosis [147]. CENP-E 
is important for ensuring proper chromosome segrega-
tion and correct chromosome numbers in daughter cells 
by acting as a motor protein to transport and align chro-
mosomes at the spindle equator [148]. The exact role that 
FANCA plays with its binding partner CENP-E has not 
been determined, but exemplifies another potential area 
of interest involving FANCA’s regulation of mitotic pro-
cesses to ensure chromosome fidelity in dividing cells. 
Improper chromosome congression can cause lagging 
chromosomes, a known phenotype of FANCA null cells 
[142]. Perhaps FANCA assists CENP-E in its assembly 
of chromosomes at the spindle equator, preventing the 
occurrence of improperly separated chromosomes.
Potential mitotic FANCA/MUS81–EME1 function
It is possible that the regulation of FANCA on MUS81–
EME1 has implications for maintaining genomic sta-
bility in early mitosis. MUS81–EME1 co-localizes to 
UFB resulting from common fragile sites along with 
FANCD2–FANCI in prometaphase, showing that 
MUS81–EME1 already works in concert with the FA 
pathway in this process. Depletion of MUS81 leads to an 
increased number of UFB stemming from CFS, highlight-
ing its importance in maintaining chromosome fidelity 
at these CFSs prior to the completion of mitosis [149]. 
MUS81 has also been shown to induce programmed 
breaks at CFSs in late G2/early mitosis, a process that 
seems to be very important for successful sister chro-
matid separation [149]. Because FANCA has recently 
shown its ability to control the endonuclease activity of 
MUS81–EME1, it is feasible for FANCA to potentially 
regulate MUS81–EME1 in its cleavage activity at CFS in 
early mitosis. Creating programmed DNA breaks must 
be tightly regulated in order to prevent aberrant lesions, 
so other regulatory molecules most likely intervene in 
these processes in order to guarantee that these nucleases 
perform their cutting activity on the proper substrate at 
the appropriate time. FANCA has already been shown 
to regulate this activity of MUS81–EME1 at replication 
forks stalled by interstrand crosslinks [38]. FANCA has 
cytoplasmic activity with several demonstrated mitotic 
roles and the FA pathway has already shown the ability 
to maintain genomic CFS stability [137]. These character-
istics support FANCA as a likely candidate to serve as a 
regulator of MUS81–EME1 incision activity at CFS dur-
ing early mitosis. The multi-faceted capacities of FANCA 
support its relevance in providing genome stability in 
G2/M phase in addition to DNA replication during S 
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phase. Apparently FANCA is more versatile than solely 
be part of the FA core complex that is involved in ICL or 
double strand break repair. We provide here a table as a 
brief summary of its known cellular functions discussed 
in this article (Table 1).
Conclusions and future directions
Understanding the DNA damage response’s impact 
on genome instability is crucial for advancing cancer 
research. There is a “malignant threshold” for the amount 
of assault the genome can handle before becoming at risk 
for oncogenic transformation [153]. Research has shown 
that the DNA damage response (DDR) (ATM-CHk2-p53) 
is over-active in pre-malignant tissues, and is also indica-
tive of replicative stress [154]. This constitutive activation 
provides selective pressure for cells to acquire resist-
ance to these checkpoints through a genetic instability 
mechanism conferred by such replication stress. Muta-
tions in tumor suppressors or proto-oncogenes resulting 
from genome instability allow the evasion of apoptosis 
or senescence induced by the DDR, as previously men-
tioned in the instances of FA-driven AML. In order to 
maintain viability along with unrestrained growth and 
proliferation, cancer cells must walk a narrow path of 
allowing pro-oncogenic mutations while prohibiting a 
fatal amount of cytotoxicity. Because genomic instabil-
ity seems to be necessary for this feat, understanding 
the molecular players that have a role in up-keeping this 
balance will be essential for determining the factors that 
allow malignant transformation to occur. Fanconi anemia 
proteins have functions in absolving the replication stress 
that promotes genomic instability, so greater knowledge 
of their involved pathways could provide helpful clues in 
elucidating the events that lead up to tumorigenesis.
The actions of FA proteins in protecting the genome 
could indicate their potential as therapeutic targets in 
drug discovery. Cancerous cells overcoming the DDR 
while preventing the threshold of damage that renders 
them unviable often leads to a dependence on certain 
DNA repair factors in the absence of others. The syn-
thetic lethal approach in cancer drug development has 
become extremely popular due to this occurrence. Tar-
geting the molecules for inhibition that cancer cells rely 
on to maintain a basal requirement of genomic stabil-
ity has shown effectiveness in some specific cancers. 
The most popular example exploits the dependency of 
BRCA1 and BRCA2 deficient cancers on the base exci-
sion repair protein PARP1, leading to the development 
of PARP inhibitors (PARPi) [155]. PARPi have already 
made their way to clinical trials where they are showing 
promising results, especially in combination with other 
therapies such as chemotherapy, radiation, and CHK1 
inhibitors [156]. The success of these personalized small 
molecule inhibitors has inspired researchers to search for 
the next therapeutic targets that specific cancers will be 
sensitive to, while having minimal effects on normal cells. 
It appears that the targets that seem to have the great-
est potential are proteins that function in DNA damage 
Table 1 Known cellular functions of FANCA
Pathway Molecular action Reference
DNA damage response
 Within the FA core com-
plex
Part of A-G20 subcomplex, essential for the ubiquitination of FANCD2 [35]
Intrinsically binds with ds and ssDNA, and RNA [37]
Phosphorylated at S1149, crucial for complex activity [40]
Involved in R-loop resolution [35, 78]
Promotes double strand break repair through homologous. Recombination and single strand annealing [68, 106]
 Out of the FA core complex Regulates MUS81–EME1 incision activity at ICL [38]
Interacts with and regulates XPF’s incision activity at both 5′ and 3′ of ICL [90, 92]
SH3 mediated FANCA αIISP interaction stabilizes αIISP [90, 101, 102]
Promotes FEN1 endonuclease activity [103]
Others
 Oxidative stress mitigation Enhances cell survival in pro-oxidant conditions [120, 121]
Oxidative stress induced FANCA/BRG1/promoter complex protects antioxidant defense gene [130]
 Mitotic stress mitigation Involved in the maintenance of normal spindle assembly [142]
T351 phosphorylation by NEK2 may plays a role in preserving centrosome integrity [144]
N terminus interacts with CENP-E and regulates chromosome alignment [147]
 Cell migration and motility Modulates CXCR5 neddylation through an unknown mechanism and further stimulates cell migration 
and motility
[150]
Direct and indirect transcriptional regulation through HES1, potential in promoting EMT [151, 152]
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repair, cell cycle regulation, and mitosis. Coincidentally, 
these are all pathways in which FA proteins also func-
tion. Previous attempts to develop Ku/DNA-PK inhibi-
tors, ATR/CHK1 inhibitors, and Rad51 inhibitors have 
resulted in excessively cytotoxic and non-specific agents 
that are too impractical for clinical use [157]. Fanconi 
Anemia proteins have already demonstrated their poten-
tial to promote cancer growth and drug resistance in 
certain contexts. The dependence of BRCA1/2 cancers 
on FANCD2 in promoting Alt-EJ [74] makes exploita-
tion of the FA pathway an attractive option for targeted 
therapies.
FANCA is able to promote error-prone repair pathways 
such as SSA that permit cancer-driving genomic insta-
bility. Manipulating this activity could be useful in pre-
venting DNA damage repair in certain tumors that rely 
on these pathways, resulting in their death. Inhibiting the 
canonical FA pathway could have a myriad of toxic effects 
on cancer cells by sensitizing them to crosslinking agents 
or by inducing mitotic catastrophe through improper 
centrosome number regulation. Further research will 
be needed to evaluate the effects that targeting the FA 
pathway and its individual components will have on both 
cancerous cells as well as non-cancerous human tissues. 
In support of FA protein targeted therapy, it has been 
observed that the regulation of FA proteins does contrib-
ute to the success of tumors. Promoter hypermethylation 
of FANCF is observed in cases of AML [158] and ovar-
ian cancer [159]. On the other hand, hypomethylation of 
FANCA promoters in squamous cell carcinoma of lar-
ynx (LSCC) cells has also been shown [160], which could 
mean that higher expression levels of these proteins 
contribute to oncogenic potential. Consistent with this, 
FANCA expression is up-regulated in basal breast tumors 
compared with non-basal breast tumors, and has higher 
expression levels in RB1-mutated retinoblastomas than 
MYCN-amplified retinoblastomas [161].
Studying FA proteins and the pathways in which they 
act might additionally explain some of the mechanisms 
used by cancer to alter cellular processes for their own 
benefit. The biochemical analysis of Fanconi anemia pro-
teins has already provided a wealth of information detail-
ing the many ways that cells preserve their sacred genetic 
code, but much more future research remains. Because 
altered levels of FA proteins have proven to be patho-
genic, the study of how the activities of these proteins 
are regulated will assist in deciphering their full mecha-
nisms of action. Exploring the genetic regulation and 
gene expression profiles of FA proteins could explain how 
their silencing or overexpression contributes to carcino-
genesis. It has recently been discovered that p53 is able 
to down-regulate the FA pathway, and that high grade 
carcinomas (ovarian and adenocarcinomas) exhibit p53 
loss and subsequent overexpression of at least 6FA pro-
teins including FANCD2 and FANCA [162]. Whether 
this FA overexpression promotes cancerous pathways or 
not remains to be discovered but is nevertheless impor-
tant for delineating the genetic changes that characterize 
tumor progression. Additional discoveries of epigenetic 
regulation, post-translational modifications, and regula-
tory binding partners will contribute to an understand-
ing of how proper FA expression and activation protects 
the genome. There is a plethora of disease mutants to 
be studied that can expand further characterization of 
FA proteins’ biochemical properties. Protein, DNA, and 
RNA interactions that have already been discovered 
must be studied more in depth to establish significance 
in respective pathways. It has been over 20  years since 
the first FA protein was cloned [163], and a vast amount 
of information pertaining to their roles in hereditary 
disease as well as sporadic cancers through the enable-
ment of genomic instability has been discovered through 
diligent research. Continuing to explore the functions of 
these proteins will provide more valuable insight into the 
cellular processes that protect our genome and govern 
our health, while also enlightening us to future therapeu-
tic treatments for instability disorders and cancer.
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